Viridian Therapeutics, Inc.\DE
About Viridian Therapeutics, Inc.\DE
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $4.0M
- Net income
- -$342.6M
- Total assets
- $899.4M
- Market cap
- $1.7B
- Operating margin
- -512.9%
- Net margin
- -483.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $70.8M
- Operating expenses
- $434.2M
- Operating income
- -$363.4M
- Income tax
- $0
- Net income
- -$342.6M
Balance sheet
- Total assets
- $899.4M
- Current assets
- $894.2M
- Total liabilities
- $177.3M
- Current liabilities
- $70.7M
- Shareholders’ equity
- $722.2M
Cash flow
- Operating cash flow
- -$276.4M
- Investing cash flow
- -$37.6M
- Financing cash flow
- $426.7M
- Net cash flow
- $112.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.7B
- Shares outstanding
- 110.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 18, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $342.6M in FY2017.
- Revenue grew 2291% from FY2021 to FY2025.
- Trading 53% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Viridian Therapeutics, Inc.\DE.
Write a review
News about Viridian Therapeutics, Inc.\DE
News & sentiment via Polygon.io
